Accessibility Menu
 
ProQR Therapeutics logo

ProQR Therapeutics

(NASDAQ) PRQR

Current Price$1.78
Market Cap$189.65M
Since IPO (2014)-87%
5 Year-72%
1 Year+61%
1 Month-1%

ProQR Therapeutics Financials at a Glance

Market Cap

$189.65M

Revenue (TTM)

$15.90M

Net Income (TTM)

$42.10M

EPS (TTM)

$-0.45

P/E Ratio

-3.96

Dividend

$0.00

Beta (Volatility)

1.35 (Average)

Price

$1.78

Volume

21,684

Open

$1.81

Previous Close

$1.78

Daily Range

$1.75 - $1.84

52-Week Range

$1.10 - $3.10

PRQR: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProQR Therapeutics

Industry

Biotechnology

Employees

186.6

CEO

Daniel Anton de Boer

Headquarters

Leiden, 2333 Ck, NL

PRQR Financials

Key Financial Metrics (TTM)

Gross Margin

96%

Operating Margin

-3%

Net Income Margin

-3%

Return on Equity

-64%

Return on Capital

-54%

Return on Assets

-37%

Earnings Yield

-25.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$189.65M

Shares Outstanding

105.36M

Volume

21.68K

Short Interest

0.00%

Avg. Volume

444.03K

Financials (TTM)

Gross Profit

$12.68M

Operating Income

$42.15M

EBITDA

$39.56M

Operating Cash Flow

$50.71M

Capital Expenditure

$979.75K

Free Cash Flow

$51.69M

Cash & ST Invst.

$92.37M

Total Debt

$13.99M

ProQR Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$4.64M

+7.8%

Gross Profit

$3.97M

-7.8%

Gross Margin

85.52%

N/A

Market Cap

$189.65M

N/A

Market Cap/Employee

$1.14M

N/A

Employees

166

N/A

Net Income

$8.84M

+5.0%

EBITDA

$8.37M

-43.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$78.39M

-40.7%

Accounts Receivable

$5.08M

N/A

Inventory

$0.00

N/A

Long Term Debt

$9.54M

-13.8%

Short Term Debt

$4.44M

-27.8%

Return on Assets

-37.35%

N/A

Return on Invested Capital

-54.05%

N/A

Free Cash Flow

$13.59M

-43.4%

Operating Cash Flow

$13.07M

-39.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACHVAchieve Life Sciences, Inc.
$3.58+2.58%
ARCTArcturus Therapeutics Holdings Inc.
$8.46+1.20%
EDITEditas Medicine, Inc.
$3.20+8.84%
MREOMereo BioPharma Group plc
$0.32-2.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.37+0.10%
INTCIntel
$65.18+0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.81+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$50.66+0.03%

Questions About PRQR

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.